Phase III Study to Explore the Effects of Eligen(R) Delivery Technology and
Salmon Calcitonin on Vertebral Fractures in Postmenopausal Women
CEDAR KNOLLS, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that Novartis Pharma AG has finished recruitment for a multi-center Phase III study exploring the safety and efficacy of Salmon Calcitonin and Emisphere's proprietary Eligen(R) Technology in the treatment of vertebral fractures in postmenopausal women aged 60-80 with osteoporosis. The last of 4,500+ patients was recruited in the final week of June, and the three-year study will be conducted in North and South America, Europe and Asia.
Osteoporosis is a disease associated with a gradual thinning and weakening of the bones, occurring most frequently in women after menopause. Thinner and weaker bones are increasingly susceptible to fractures. Untreated postmenopausal osteoporosis can lead to chronic back pain, disabling fractures, and lost mobility.
"This Phase III study provides yet another application of our Eligen(R) Technology in the fight against osteoporosis. Safe, effective and rapid treatment will make a difference in the lives of millions of American women who are afflicted with the disease," said Michael V. Novinski, President and Chief Executive Officer of Emisphere.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company that
focuses on a unique and improved delivery of therapeutic molecules using
its Eligen(R) Technology. These molecules and compounds could be currently
available or in development. Such molecules are usually delivered by
injection; in many cases, their benefits are limited due to poor
|SOURCE Emisphere Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved